8-K: Cross Country Healthcare Merger Terminated, $20M Fee

Cross Country Healthcare's merger agreement with Aya Healthcare has been terminated, resulting in a $20 million termination fee and immediate share repurchases.

Summary

• Cross Country Healthcare, Inc. (CCRN) announced the termination of its Agreement and Plan of Merger with Aya Holdings II Inc. and Aya Healthcare, Inc., originally entered into on December 3, 2024.
• The merger was terminated effective December 4, 2025, due to the failure to consummate the transaction prior to the end date under the Merger Agreement.
• Aya Healthcare will pay Cross Country Healthcare a termination fee of $20 million in cash within two business days of the termination.
• The termination was primarily a result of an extended U.S. Federal Trade Commission (FTC) review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).
• A Second Request from the FTC was received on February 20, 2025, and substantial compliance was certified on August 29, 2025.
• The HSR waiting period was extended due to a historic 43-day government shutdown, pushing its expiry to December 30, 2025, beyond the extended Merger Agreement termination date of December 3, 2025.
• Cross Country Healthcare was unable to reach an agreement with Aya Healthcare to amend and extend the Merger Agreement beyond the December 3, 2025 termination date.
• Aya Healthcare cited uncertainty, time, and resource burden from a possible FTC challenge as justification for abandoning the deal.
• The Company intends to immediately commence repurchases of up to $40 million of its stock under its existing authorization.

Sentiment

Score: 4

Explanation: The termination of a significant merger is a strategic setback, indicating a failure to execute a planned growth initiative. However, the receipt of a substantial termination fee and the immediate commencement of a share repurchase program provide financial mitigation and signal management's confidence in the standalone business, preventing a lower score.

Positives

• Cross Country Healthcare will receive a $20 million cash termination fee from Aya Healthcare.
• The Company plans to immediately commence repurchases of up to $40 million of its stock under an existing authorization, signaling confidence and returning value to shareholders.
• Management expressed confidence in the Company's operational resilience, diversification, financial strength, AI-driven capabilities, tech-savviness, strong cash position, and lack of debt.
• The Company is focused on executing its strategic plan to drive accelerated growth and deliver long-term shareholder value.
• The Company will celebrate 40 years of industry leadership and clinical excellence in 2026.

Negatives

• The Agreement and Plan of Merger with Aya Healthcare, Inc. has been terminated, preventing the planned acquisition.
• Cross Country Healthcare's efforts to advocate for a shortened FTC review period were unsuccessful.
• The Company was unable to reach an agreement with Aya Healthcare to amend and extend the Merger Agreement beyond the December 3, 2025 termination date.
• Aya Healthcare justified abandoning the deal by referencing the uncertainty, time, and resource burden resulting from a possible challenge by the FTC.

Risks

• The termination of the Merger Agreement could have adverse effects on the market price of the Company's common stock.
• The termination could adversely affect the Company's ability to retain customers and key personnel, and maintain relationships with its suppliers and customers.
• There is a risk of unexpected costs, impairments, fees, charges, or expenses resulting from the proposed merger and its termination.
• Potential litigation relating to the merger could be instituted against the parties or their directors, managers, or officers.
• Worldwide economic or political changes could affect the markets the Company serves, impacting demand for services and profitability.
• Effects from global pandemics, epidemics, or other public health crises could impact the Company.
• Changes in marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, and customer needs, pose risks.
• Disruptions in global credit and financial markets, including diminished liquidity and credit availability, changes in international trade agreements, cyber-security vulnerabilities, foreign currency volatility, swings in consumer confidence and spending, costs of providing services, retention of key employees, and outcomes of legal proceedings, claims, and investigations.

Future Outlook

Management expects to continue executing its strategic plan, driving accelerated growth, advancing innovation, driving efficiencies, and capturing significant opportunities as a standalone entity. The Company aims to deliver long-term value for shareholders, leveraging its operational resilience, diversification, financial strength, and tech-savvy approach.

Management Comments

• "Although the outcome is not what we envisioned, we believe we are well-positioned to continue executing our strategic plan and drive accelerated growth."
• "The Company is operationally resilient, well diversified across the continuum of care and fully focused on delivering long-term value for our shareholders."
• "We are a financially strong, AI driven and tech savvy organization with a strong cash position and no debt."
• "I am incredibly proud of our teams persistence and professionalism throughout the lengthy FTC review process. Their commitment has only strengthened our momentum."
• "With clarity around our standalone path, we are energized and excited to continue advancing innovation, driving efficiencies, and capturing the significant opportunities ahead."

Industry Context

The termination of this merger highlights the increasing regulatory scrutiny, particularly from the FTC, on consolidation within the healthcare staffing and workforce solutions industry. Despite the setback, Cross Country Healthcare positions itself as a market-leading, tech-enabled firm, suggesting a focus on innovation and efficiency to navigate competitive and regulatory landscapes.

Stakeholder Impact

• Shareholders: Will not realize the benefits of the merger, but will receive value through the $20 million termination fee and the immediate $40 million share repurchase program. Potential for adverse effects on stock price.
• Employees: Risk of inability to retain key personnel following the merger termination.
• Customers and Suppliers: Risk of inability to maintain relationships with customers and suppliers.

Next Steps

• Immediately commence share repurchases under the existing $40 million authorization.
• Continue executing the strategic plan to drive accelerated growth.
• Advance innovation and drive efficiencies within the Company.
• Capture significant opportunities as a standalone entity.

Key Dates

Recommendation

The termination of a strategic merger is a significant negative event, removing a potential growth catalyst and introducing uncertainty. However, the immediate receipt of a $20 million termination fee and the commitment to an immediate $40 million share repurchase program provide a financial cushion and demonstrate management's confidence in the Company's standalone prospects. The Company's stated financial strength, lack of debt, and focus on organic growth and innovation suggest resilience. Investors should hold to assess the Company's performance on its standalone strategic plan and monitor market reaction, balancing the strategic setback against the financial mitigation and management's positive outlook.

Keywords

Healthcare staffing, Merger termination, Share repurchase, FTC review, HSR Act, Workforce solutions, CCRN, Corporate governance